Global Acromegaly and Gigantism Treatment market
Global Market for Acromegaly and Gigantism treatment was worth $1.4 Bn in 2019 and is expected to grow at a CAGR of 4.4% in the forecast period, reaching a value of $2.2 Bn.
Market Introduction and Overview
Acromegaly is a rare and severe disease caused by an increased, autonomous secretion of the Growth Hormone (GH), resulting in high circulating levels of insulin-like growth factor 1 (IGF-1). The comorbidities and mortality rate are closely related to the disease duration. The current treatment for acromegaly includes neurosurgery, radiotherapy and medical therapy. Transsphenoidal surgery often represents the recommended first-line treatment.
Gigantism is a rare condition that causes abnormal growth in human beings. A tumour in the pituitary gland is the major reason for the condition to occur. The abnormal growth is notable in terms of height as well as girth of the body. Common symptoms for the early diagnosis of this disease include- very large hand and feet, thick toes and fingers and coarse facial features.
Acromegaly and gigantism is a rare disease prevailing 2.8 to 13.7 cases per 1 lakh people. The increasing prevalence of the disease is the major factor driving the market growth. Rise in other chronic disorders such as carney complex and development of novel therapy treatments are also aiding the market growth. The first-generation somatostatin receptor ligands (SRLs) are the drug choice in patients after surgery. Other available drugs approved for clinical use are the second-generation SRL pasireotide, Dopamine agonist- Cabergoline and the GH-receptor antagonist Pegvisomant.
The increase in patient number and demand for medications to cure the disease is fuelling the market growth. According to the American cancer Society, around ten thousand pituitary tumors are diagnosed each year in America. Also, strong pipelines for drugs, increasing awareness, changing lifestyles and increasing investments in R&D for developing new therapeutics are driving the market upwards.
The report covers the detailed analysis of global market for Acromegaly and Gigantism treatment with the classifications of the market based on treatment type, end-user and region. Analysis of past market dynamics from 2016 to 2019 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key players contribution in it.
The report has profiled seven key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques. Report has come up with recommendations for future hot spot in APAC region. New research findings, funding policies for projects and its impact on Acromegaly and Gigantism treatment market are covered in the report
Global Acromegaly and Gigantism Treatment market
Segment Analysis
Somatostatin Analogs is expected to hold the major market share of xx%
Somatostatin analogs segment (SSAs) accounted for the largest market share in revenue terms in 2019. SSAs have been prescribed as the first line of treatment for acromegaly and gigantism by physicians. The currently available marketed drugs are Sandostatin LAR, Signifor LAR and Somatuline. Novartis and Ipsen Pharma are the key players who developed and marketed the drugs, contributing to the market growth.
A strong pipeline of drugs is expected to fuel up the market growth in forecast period. Many more drugs are under clinical trials and are expected to be approved soon. Currently, two GHRIs are in the pipeline such as ISIS 766720 by Ionis pharmaceuticals. It is undergoing a phase II clinical trial and is expected to soon get approved by the FDA.
Market segmentation
The Global Market for Acromegaly and Gigantism treatment is segmented based on-
Treatment Type
• Surgery
• Radiation therapy
• Medication
Somatostatin analogs
GH Receptor Antagonists
Dopamine Antagonists
End Users
• Hospitals
• Clinics
• Home Care
Regional Insights
Global Acromegaly and Gigantism Treatment market1
North America generated a revenue of $xx Mn in 2019 and is expected to emerge as a dominant region in the forecast period. Increasing prevalence of the disease, growing research activities, advanced treatment techniques, favourable reimbursement policies, development of novel products are the multiple factors boosting the growth of market in this region. Moreover, the efforts of key players in developing new and efficient drug pipelines is boost the regional demand for market.
Asia Pacific is expected to witness growth in the forecast period. Owing to the increasing population and rising diabetic cases, growing healthcare facilities in developing nations and advanced treatment options, the market in this region is anticipated to grow. Sun Pharma and WOCKHARDT are developing new formulations for octreotide molecule and is currently in the pre-clinical phase. The approval of this is expected to exhibit a major hike in the APAC market.
Key players operating the Global Acromegaly and Gigantism Treatment Market
• Pfizer Inc
• Chiasma Inc
• Novartis AG
• Crinetics Pharmaceuticals
• Ionis Pharmaceuticals Inc
• Midatech Pharma Inc
• Validus Pharmaceuticals LLC
The report also helps in understanding Global Acromegaly and Gigantism Treatment Market dynamics, structure by analysing the market segments and project the Global Acromegaly and Gigantism Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Acromegaly and Gigantism Treatment Market make the report investor’s guide.
For more information of visit:https://www.maximizemarketresearch.com/market-report/global-acromegaly-and-gigantism-treatment-market/82292/
This Report Is Submitted By : Maximize Market Research Company
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
